dbo:abstract
|
- The ristocetin-induced platelet aggregation (RIPA) is an ex vivo assay for live platelet function. It measures platelet aggregation with the help of von Willebrand factor (vWF) and exogenous antibiotic ristocetin added in a graded fashion. It is similar to the ristocetin cofactor assay but has the added benefit in that it helps in the diagnosis of type 2B/pseudo von Willebrand disease (vWD) and Bernard–Soulier syndrome because it uses patient's live endogenous platelets, whereas ristocetin cofactor assay tests the function of only the vWF and not the platelets. Ristocetin cofactor assay uses the patient's platelet poor plasma (with vWF but no platelets) and adds ristocetin and exogenous formalin-fixed platelets which can passively agglutinate (but not actively aggregate, as they are dead). Formalin does not allow the extrinsic platelets to secrete the vWF of their α-granules, and thus only the activity of the intrinsic vWF is tested. In an unknown fashion, the antibiotic ristocetin causes von Willebrand factor to bind the platelet receptor glycoprotein Ib (GpIb), so when ristocetin is added to normal blood, it causes agglutination of fixed platelets or initiates the initial agglutination phase of aggregation of live platelets. The results of the ristocetin-induced platelet aggregation in some characteristic diseases are the following:
* Type 1 vWD: hypoactive agglutination occurs (consistent with ristocetin cofactor assay results)
* Type 2A vWD: hypoactive agglutination occurs (consistent with ristocetin cofactor assay results)
* Type 2B vWD: hyperactive agglutination occurs (when the ristocetin cofactor assay is used, the agglutination is hypoactive)
* Type 2M vWD: hypoactive agglutination occurs (consistent with ristocetin cofactor assay results)
* Type 2N vWD: normal agglutination occurs (consistent with ristocetin cofactor assay results)
* Type 3 vWD: no agglutination occurs (consistent with ristocetin cofactor assay results)
* Pseudo-vWD: hyperactive agglutination occurs (when the ristocetin cofactor assay is used, the agglutination is hypoactive)
* Bernard-Soulier syndrome: hypoactive agglutination occurs (when the ristocetin cofactor assay is used, the agglutination is normal) INTERPRETATION OF TESTRAT+ Ve= normal (gp1b & vWF present)RAT-ve=abnormal(gp1b & vWF absent) (en)
- Aglutynacja płytek indukowana ristocetyną (ang. RIPA – Ristocetin Induced Platelet Agglutination) – badanie in vitro aktywności czynnika von Willebranda, służące do diagnozowania choroby von Willebranda. Posiada przewagę nad, wykorzystywanym również w diagnostyce tej choroby, badaniem , ponieważ umożliwia wykrycie typu 2B VWD oraz zespołu Bernarda-Souliera. Antybiotyk ristocetyna indukuje łączenie czynnika von Willebranda do receptora płytkowego – (GPIb), co w efekcie powoduje aglutynację płytek krwi. (pl)
|
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 3741 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:name
|
- Ristocetin-induced platelet aggregation (en)
|
dbp:purpose
|
- It measures platelet aggregation with the help of von Willebrand factor (en)
|
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Aglutynacja płytek indukowana ristocetyną (ang. RIPA – Ristocetin Induced Platelet Agglutination) – badanie in vitro aktywności czynnika von Willebranda, służące do diagnozowania choroby von Willebranda. Posiada przewagę nad, wykorzystywanym również w diagnostyce tej choroby, badaniem , ponieważ umożliwia wykrycie typu 2B VWD oraz zespołu Bernarda-Souliera. Antybiotyk ristocetyna indukuje łączenie czynnika von Willebranda do receptora płytkowego – (GPIb), co w efekcie powoduje aglutynację płytek krwi. (pl)
- The ristocetin-induced platelet aggregation (RIPA) is an ex vivo assay for live platelet function. It measures platelet aggregation with the help of von Willebrand factor (vWF) and exogenous antibiotic ristocetin added in a graded fashion. It is similar to the ristocetin cofactor assay but has the added benefit in that it helps in the diagnosis of type 2B/pseudo von Willebrand disease (vWD) and Bernard–Soulier syndrome because it uses patient's live endogenous platelets, whereas ristocetin cofactor assay tests the function of only the vWF and not the platelets. Ristocetin cofactor assay uses the patient's platelet poor plasma (with vWF but no platelets) and adds ristocetin and exogenous formalin-fixed platelets which can passively agglutinate (but not actively aggregate, as they are dead). (en)
|
rdfs:label
|
- Ristocetin-induced platelet aggregation (en)
- Aglutynacja płytek indukowana ristocetyną (pl)
|
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageDisambiguates
of | |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is rdfs:seeAlso
of | |
is foaf:primaryTopic
of | |